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Abstract
Glomerular diseases are commonly characterized by podocyte injury including apoptosis, actin cytoskeleton rearrangement
and detachment. However, the strategies for preventing podocyte damage remain insufficient. Recently autophagy has
been regarded as a vital cytoprotective mechanism for keeping podocyte homeostasis. Thus, it is reasonable to utilize this
mechanism to attenuate podocyte injury. Trehalose, a natural disaccharide, is an mTOR independent autophagy inducer. It
is unclear whether trehalose alleviates podocyte injury. Therefore, we investigated the efficacy of trehalose in puromycin
aminonucleoside (PAN)-treated podocytes which mimic cell damage in minimal change nephrotic syndrome in vitro. Human
conditional immortalized podocytes were treated with trehalose with or without PAN. Autophagy was investigated by
immunofluorescence staining for LC3 puncta and Western blotting for LC3, Atg5, p-AMPK, p-mTOR and its substrates.
Podocyte apoptosis and necrosis were evaluated by flow cytometry and by measuring lactate dehydrogenase activity
respectively. We also performed migration assay to examine podocyte recovery. It was shown that trehalose induced
podocyte autophagy in an mTOR independent manner and without reactive oxygen species involvement. Podocyte
apoptosis significantly decreased after trehalose treatment, while the inhibition of trehalose-induced autophagy abolished
its protective effect. Additionally, the disrupted actin cytoskeleton of podocytes was partially reversed by trehalose,
accompanying with less lamellipodias and diminished motility. These results suggested that trehalose induced autophagy
in human podocytes and showed cytoprotective effects in PAN-treated podocytes.
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Introduction
Glomerular diseases are characterized by the disrupted renal
filtration barrier which consists of endothelial cells, basement
membrane and epithelial cells (also called podocytes). Podocytes
have been regarded as the key target of harmful stimuli in renal
diseases [1]. It is evident that podocyte effacement is commonly
found in glomerular diseases such as minimal change nephrotic
syndrome (MCNS) and focal segmental glomerulosclerosis (FSGS)
[2]. In addition, the gene mutation of podocyte cytoskeleton
proteins is associated with congenital nephrotic syndrome [3–5].
Thus, the ideal therapeutic strategies of glomerular diseases are
aiming to ameliorate podocyte injury including apoptosis and actin
cytoskeleton rearrangement.
Autophagy has emerged as a potential approach recently. It is a
highly conserved catabolic mechanism of which the unwanted
organelles and misfolded proteins are delivered to lysosome for
degradation [6]. The final metabolic products can be recycled as
nutrient for keeping cell homeostasis. Podocytes are postmitotic
and long-lived cells. Therefore, strong self-protective mechanisms
are required for counteracting different detrimental challenges. As
expected, the higher basal autophagy has been demonstrated in
podocytes than other renal cells [7,8]. Autophagy deficient mice
present with accumulated dysfunction proteins, endoplasmic
reticulum stress and proteinuria. Moreover, they are more
susceptible to drug-induced models of glomerular diseases [8].
Our previous study also showed that inhibition of autophagy
increases apoptosis and actin cytoskeleton depolymerisation in
puromycin aminonucleoside (PAN)-treated human podocytes [9].
Additionally, it was reported that autophagy may become as a new
therapeutic approach for diabetic nephropathy [10]. Collectively,
it is suggested that autophagy may be harnessed for the treatment
of glomerular diseases, as it may attenuate podocyte injury by
eliminating harmful stimuli [6,11].
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Autophagy is precisely regulated by a network of proteins. For
instance, mTOR which is a highly conserved serine/threonine
kinase negatively regulates autophagy induction [12]. Rapamycin
is the representative agent for inducing autophagy via inhibition of
mTOR activity. It was demonstrated that autophagy induced by
rapamycin alleviates podocyte injury in vitro [13]. However,
proteinuria was observed in patients with organ transplantation
after rapamycin treatment [14], and the underlying mechanism
remains unclear. Even though the beneficial effects of autophagy
in renal diseases are not fully realized, it is essential to find
alternative safe autophagy inducers for the treatment of renal
diseases.
Trehalose is a natural disaccharide found in organisms from
bacteria to plants, including yeast, fungi, and invertebrates
[15,16]. It induces autophagy in an mTOR-independent manner
and shows protective effects in various cells against harmful stimuli
such as heat, dehydration, cold, desiccation, and oxidation [17].
The protective effect of trehalose has been demonstrated in
neurodegenerative diseases, such as Alzheimer’s disease, fronto-
temporal dementia, progressive supranuclear palsy and cortico-
basal degeneration [17,18]. It remains unclear whether trehalose
induces autophagy and shows cytoprotective effects in podocytes.
In the present study, we are the first to show that trehalose
induced autophagy in an mTOR independent manner in human
podocytes. Moreover, podocyte apoptosis and actin cytoskeleton
depolymerisation can be alleviated by trehalose. Therefore, this
study confirmed that autophagy can be utilized for protecting
podocytes and trehalose may be a potential candidate for the
treatment of glomerular diseases.
Methods And Materials
Cell culture
Conditionally immortalized human podocytes AB8/13 (Uni-
versity of Bristol, UK) were cultured in RPMI 1640+10% fetal
bovine serum (Life Technologies, New York, USA) [19]. The
human podocytes proliferated at non-permissive temperature
(33uC) with the addition of Insulin-Transferrin-Selenium (Life
Technologies). Cells were harvested after growing to 50–60%
confluency and passaged to permissive temperature (37uC) for full
differentiation in 10–14 days. Fully differentiated human podo-
cytes were used in the following experiments. Agents for podocyte
treatment included trehalose (10–100 mM, optimum at 50 mM),
PAN (30 mg/ml), chloroquine (CQ, 25 mm) and wortmannin (WT,
0.2 mm) (Sigma-Aldrich, Missouri, USA). The dose of both
autophagy inhibitors has been optimized in dosage titration
experiments (data not shown).
Western blotting
Total proteins in podocytes were extracted by RIPA buffer
containing phosphatase inhibitors (Calbiochem, Merck Millipore,
USA) and protein inhibitors (Roche Applied Science, Mannheim,
Germany). Bradford assay (Bio-Rad Laboratories, Munich,
Germany) was used to assess protein concentration. Equal
amounts of proteins were denatured after heating at 95uC for
5 min and separated by 4–12% SDS-PAGE. PVDF membrane
(Bio-Rad) after transferring was incubated with primary antibody
and secondary antibody. Eventually the results were visualised
using chemiluminescence substrate (Perkin Elmer, Massachusetts,
USA). The ChemiDoc MP system (Bio-Rad) was used to capture
images. The expression of proteins was analysed with the Image J
software. Rabbit anti-human LC3, Atg5, p-mTOR, T-mTOR, p-
p70S6K, p70S6K, p-4E-BP1, 4E-BP1, p-AMPK, AMPK, p62,
GAPDH and goat anti-rabbit IgG-HRP linked antibody (Cell
Signaling Technology, Massachusetts, USA) have been used with
a 1:1000 dilution.
Immunofluorescence analysis
Fixed podocytes (4% paraformaldehyde, 15 min) were blocked
with 2% BSA for 30 min. After washing in PBS three times,
podocytes were incubated with anti-LC3 antibody (4uC, 12 h).
Alexa Fluor 488 goat anti-rabbit IgG antibody (Life Technologies)
was added (room temperature, 2 h) and washed. ProLong Gold
Antifade Reagent with DAPI (Life Technologies) was used to stain
nuclei. Cells were visualised by confocal microscopy (EZ-C1,
Nikon Instrument, Japan). Furthermore, Alexa Fluor 594 Phalloi-
din (Life Technologies) was used for Filamentous actin (F-actin)
staining. The percentage of podocytes showing accumulation of
LC3 puncta (that is with at least five puncta per podocyte) were
counted and podocyte with disrupted cytoskeleton was quantified
as the previous study described [9,20]. The lamellipodias per cell
were calculated following the method described before [21]. At
least 100 cells were scored in each of the six independent
experiments.
Reactive oxygen species (ROS) measurement
Podocytes were cultured in RPMI 1640 free of phenol red (Life
Technologies) in black 96-well plates (Perkin Elmer). Differenti-
ated podocytes were incubated with 10 mM CM-H2DCFDA (Life
Technologies) or vehicle alone (20 min), followed with trehalose
treatment (50 mM). After recovering for 0.5 hour (37uC), immu-
nofluorescence was recorded using the VICTOR 3 plate reader
(Perkin Elmer). The fluorescence intensity was calculated and
analysed as described previously [22].
Necrosis measurement
Equal number of podocytes was seeded in 6-well plates.
Podocyte necrosis was evaluated by measuring lactate dehydroge-
nase (LDH) activity in culture medium. The CytoTox 96 Non-
Radioactive Cytotoxicity Assay (Promega, Wisconsin, USA) was
used for assessing LDH activity. The manufacture’s protocol was
strictly followed [23].
Migration assay
Fully differentiated podocytes in 6-well plates were scratched by
two strokes with a sterile 0.4 mm 200 ml Gilson style extension
length tip. Podocytes were treated by PAN and/or trehalose for
12 h. The number of podocytes migrating into the gap was
counted as described before [23].
Apoptosis measurement
Podocytes were harvested after treatment and the cell density
was adjusted to 16106/ml. (1) YO-PRO-1/PI assay (Life
Technologies). 1 ml of podocytes suspension was incubated with
1 ml YO-PRO-1 and 1 ml PI solution for 30 min on ice. Apoptotic
cells were measured by flow cytometer (FC500, Beckman Coulter,
California, USA) and expressed as a percentage of total cells. (2)
Anti-active caspase-3 assay. PE-conjugated active caspase-3
antibody (BD Pharmingen, California, USA) was used to stain
podocytes which were pre-incubated with Cytofix/Cytoperm
solution. Cells were resuspended in BD Perm/Wash buffer and
the percentage of active caspase-3 positive podocytes was analysed
by flow cytometry. Examples of plots and analysis are shown in
our previous study [9].
Trehalose Alleviates Human Podocyte Injury
PLOS ONE | www.plosone.org 2 November 2014 | Volume 9 | Issue 11 | e113520
Statistical Analysis
Data were expressed as mean 6 SEM. T-test was used for two
group’s comparison. Multiple groups were analysed by Kruskal-
Wallis test with post hoc procedures using the Prism 5.0 Software
(GraphPad, San Diego, CA, USA). A p value ,0.05 was
considered to be statistically significant. n denotes the number of
independent experiments performed.
Results
Trehalose induced autophagy in human podocytes
To test whether trehalose induces autophagy in human
podocytes, we investigated the expression of LC3 and Atg5 in
treated cells. Briefly, LC3 consists of LC3-I and LC3-II, LC3-I
converts into LC3-II which adheres to the membrane of
phagophore for the formation of autophagosome. LC3-II presents
with bright puncta in immunofluorescence staining [24]. Atg5 is
essential for the elongation of autophagosome [25]. As shown in
Figures 1A–1B, the expression of LC3-II increased in a dosage
and time dependent manner, the immunofluorescence staining
results were consistent with these findings. The LC3-II puncta
positive podocytes significantly increased in the cytoplasm after
36 h-trehalose treatment (Figures 1C–1D). In addition, the
significant increased expression of Atg5 was found at the time
point of 60 h (Figure 1E).
Trehalose induced podocyte autophagy in an mTOR
independent manner
mTOR negatively regulates autophagy induction, whereas
trehalose triggers autophagic flux in other cell types such as
neuron without altering the phosphorylation level of phospho-
mTOR (p-mTOR) [17]. It remains unknown whether the same
pathway occurs in trehalose-treated podocytes. We measured the
phosphorylation level of p-mTOR and its substrates p-p70S6K, p-
4E-BP1. As shown in Figures 2A–2C, these three markers did not
changed significantly over the 60 h treatment.
Figure 1. Trehalose induced autophagy in human podocytes. (A) The expression of LC3-II increased in a dosage dependent manner.
Conditionally immortalized human podocytes were treated with 0, 10, 50 and 100 mM of trehalose (Tre) for 48 h. LC3-II was measured by Western
blotting. The data (means 6 SEM) was expressed as the relative changes compared with Tre-0 mM group. Representative immunoblot images were
shown along with the statistical results. *p,0.05 versus Tre-0 mM, n = 5. (B) LC3-II increased in a time dependent manner. Podocytes were treated
with 50 mM Trehalose for 0, 12, 24, 36, 48 and 60 h. **p,0.01, ***p,0.001 versus Tre-0 h, n = 7. (C–D) LC3-II puncta increased after trehalose
treatment. LC3 immunostaining in podocytes was performed at 0, 12, 24, 36, 48 and 60 h after trehalose treatment (50 mM). Significant increased
green bright puncta (indicated by white arrows) can be observed in cytoplasm after 48 h-trehalose treatment. The representative LC3
immunostaining images were shown along with statistical results from 6 independent experiments. **p,0.01, ***p,0.001 versus Tre-0 h. Podocyte
nuclei were stained with DAPI (blue). (E) The expression of Atg5 was up-regulated in trehalose-treated podocytes (50 mM). Podocytes were treated
with 50 mM Trehalose for 0, 12, 24, 36, 48 and 60 h. The expression of Atg5 significantly increased at the time point of 60 h. **p,0.01 versus Tre-0 h,
n = 5.
doi:10.1371/journal.pone.0113520.g001
Trehalose Alleviates Human Podocyte Injury
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e113520
Trehalose-induced autophagy was independent of ROS
Starvation is the most common stimulus for inducing autoph-
agy. To verify whether trehalose-induced autophagy attributes to
calorie limitation, we examined the phosphorylation level of p-
AMPK which is an energy sensor in mammalian cells. When the
ratio of AMP to ATP decreases, p-AMPK will increase
responsively and subsequently lead to autophagy induction by
inhibiting the activity of mTOR [26]. As shown in Figure 3A, no
significant changes existed in phosphorylation level of p-AMPK.
The underlying mechanism of starvation-induced autophagy is the
generation of ROS which is essential for the initiation of
autophagic flux [27]. Therefore, to confirm whether ROS is
involved in the trehalose-induced autophagy, we monitored the
ROS production. Consistently, ROS did not change significantly
when compared with control group (Figure 3B).
Trehalose decreased PAN-induced apoptosis in human
podocytes via the induction of autophagy.
Interplay exists between autophagy and apoptosis. It has been
reported that autophagy suppresses cell apoptosis by inhibiting
apoptotic proteins [28]. Since trehalose can induce autophagy in
podocytes without increasing ROS, we hypothesized that trehalose
decreases podocyte apoptosis. PAN was used to induce podocyte
apoptosis in vitro. We found that trehalose up-regulated the
expression of LC3-II in PAN-treated human podocytes (Fig-
ure 4A). The data of LC3 immunostaining confirmed this finding
as LC3-II bright puncta were obviously presented in trehalose
alone and PAN+ Tre groups (Figures 4B–4C). To confirm the
protective effects of trehalose, LDH was measured to evaluate
podocyte necrosis. As shown in Figure 4D, the changes in LDH
level was negligible. However, PAN-induced apoptosis was
significantly down-regulated after trehalose treatment, accompa-
Figure 2. Trehalose induced podocyte autophagy in an mTOR independent manner. mTOR activity was not altered in trehalose-treated
podocytes. Podocytes were treated with trehalose (50 mM) for 0, 12, 24, 36, 48 and 60 h. The phosphorylation level of p-mTOR (A) and its substrates
p-p70S6K (B) and p-4E-BP1 (C) were measured by Western blotting, n = 5, 5 and 6 respectively. However, no significant changes were observed. The
representative immunoblot was shown along with the statistical results.
doi:10.1371/journal.pone.0113520.g002
Figure 3. Trehalose-induced podocyte autophagy was independent of ROS. Trehalose-induced autophagy was not associated with energy
restriction and ROS. (A) Trehalose-treated podocytes (50 mM) were harvested for p-AMPK measurement at the time points of 0, 12, 24, 36, 48 and
60 h. The phosphorylation level of p-AMPK did not change significantly. n = 6. (B) ROS level was recorded every half an hour after trehalose treatment
(50 mM), the data representing immunofluorescence intensity within 2.5 h were shown (n= 6). No significant changes were noted.
doi:10.1371/journal.pone.0113520.g003
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nying with the decrease in active caspase-3 positive cells
(Figures 4E–4F).
To verify whether the cytoprotective effects of trehalose are
attributed to autophagy induction, chloroquine (CQ) and
wortmannin (WT) were used to inhibit autophagy. CQ blocks
the fusion between autophagosome and lysosome, resulting in an
accumulation of LC3-II. WT, a potent and specific phosphatidy-
linositol 3-kinase (PI3-K) inhibitor, inhibits autophagy at the initial
stage with the decreased LC3-II [29]. As shown in Figures 5A-5B,
CQ increased the expression of LC3-II in trehalose-treated
groups. Meanwhile, WT showed the opposite pattern. In order
to confirm the inhibitory effect of CQ and WT, we also measured
the expression of p62 (also named SQSTM1) which oligomerizes
polyubiquitinated proteins and binds to LC3 on the autophago-
some membrane [30]. Eventually, these labelled damaged
organelles or unfolded proteins will be degraded in the autophagy
pathway. Thus, the inhibition of autophagy should result in p62
accumulation. As shown in Figure 5C, the expression of p62 was
up-regulated when trehalose-induced autophagy was inhibited by
CQ or WT. This pattern of expression was also observed when
CQ or WT were added to the PAN+ Tre group (PAN+ Tre+CQ
and PAN+ Tre+ WT group respectively). LDH increased
significantly when trehalose-induced autophagy was being inhib-
ited (Figure 5D). Correspondingly, podocyte apoptosis increased
after CQ or WT treatment as well as the percentage of active
caspase-3 positive podocytes (Figures 5E–F).
Trehalose alleviated PAN-induced actin cytoskeleton
injury in human podocytes
The actin cytoskeleton is the major mechanical support for
maintaining the integrity and contractility of podocytes [1]. PAN-
treated podocytes are characterized by the disrupted actin
cytoskeleton and generation of lamellipodia (Figure 6A). After
trehalose treatment, the percentage of podocytes with disrupted
actin cytoskeleton decreased as well as the number of lamellipodias
(Figure 6B–6C).
Figure 4. Trehalose decreased PAN-induced apoptosis in human podocytes. Podocyte were treated with PAN (30 mg/ml) or/and Trehalose
(50 mM) for 48 h. (A) Trehalose induced autophagy in PAN-treated human podocytes. The expression of LC3-II slightly increased after 48 h PAN
treatment, while it dramatically up-regulated in Tre and PAN+ Tre groups. Representative immunoblot images were shown along with the statistical
results. **p,0.01 versus CON, n= 6. (B–C) The findings of (A) were confirmed by LC3 immunostaining. Obvious elevated LC3-II bright green puncta
(indicated by white arrows) were visualized in trehalose-treated groups (Tre and PAN+ Tre groups), the representative images and statistical results
were shown. Nuclei were stained in blue. **p,0.01, ***p,0.001 versus CON, n = 6. (D) No significant changes were observed in podocyte necrosis.
LDH in culture medium of 4 groups was measured, n = 4. (E) Elevated apoptosis in PAN-treated podocytes was decreased by trehalose. Apoptosis was
measured by flow cytometry with YO-PRO-1/PI assay. Podocyte apoptosis was induced by PAN and decreased significantly by trehalose. *p,0.05,
**p,0.01 versus CON, n = 8. (F) The findings of (E) were confirmed by the data of active caspase-3 measurement. The active caspase-3 positive
podocytes were measured by flow cytometry. The changes pattern was similar to podocyte apoptosis measured by YO-PRO-1/PI assay. **p,0.01
versus CON, n = 7.
doi:10.1371/journal.pone.0113520.g004
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Trehalose diminished cell motility in PAN-treated human
podocytes
The limited physiological motility is essential for keeping
podocytes in normal function. Either enhanced or low level
motility of podocytes is detrimental and considered to be the cause
of proteinuria [1]. As shown in Figures 7A–7B, PAN-treated
podocytes migrated faster than control, whereas the enhanced
motility was decreased to the normal level after trehalose
treatment.
Discussion
Glomerular capillary is encircled by foot processes which
withstand high filtration pressure. Podocyte damage is regarded as
the determining factor of glomerular diseases [31]. Thus,
alleviating podocyte injury becomes the therapeutic aim. High
basal level of autophagy has been demonstrated in podocytes in
vitro and in vivo, suggesting that autophagy plays a vital role in
promoting podocyte survival [7,8]. Theoretically, autophagy
induction may ameliorate podocyte damage and autophagy
inducers may be developed as new therapeutic agents for renal
diseases. Here, we showed that PAN-induced podocyte injury was
alleviated by trehalose.
Trehalose is regarded as the autophagy inducer in neurological
studies. Moreover, the safety of trehalose is well recognized [32].
Therefore, we investigated whether trehalose provided benefits to
the damaged podocytes. Firstly, we revealed that trehalose induced
autophagy in human podocytes. The expression of LC3-II and
Atg5 in podocytes increased after trehalose treatment in a dosage
and time dependent manner. The results of LC3 immunostaining
also demonstrated that elevated LC3-II puncta were formed in
cytoplasm. Hence, trehalose is an autophagy inducer in human
podocytes and may be a potential agent for the treatment of
glomerular diseases.
mTOR is one of the most important cellular negative regulators
of autophagy [33]. Our data showed that trehalose did not
significantly alter the phosphorylation level of p-mTOR and its
substrates including p-p70S6K and p-4E-BP1. Therefore, in
accordance with the results of trehalose studies in other disciplines
such as neurology [34], our data elucidated that trehalose induced
autophagy in an mTOR independent manner in human
podocytes. To date, several mTOR independent pathways have
Figure 5. Inhibition of trehalose-induced autophagy abolished its cytoprotective effects in preventing podocyte apoptosis. CQ
(25 mM) or WT (0.2 mM) was used to inhibit podocyte autophagy which was induced by trehalose (50 mM) or trehalose (50 mM) + PAN (30 mg/ml) for
48 h. (A–C) CQ and WT inhibited trehalose-induced autophagy. The expression of LC3-II drastically increased in Tre+CQ and PAN+ Tre+CQ groups,
while it decreased significantly in Tre+WT and PAN+ Tre+WT groups. p62 slightly decreased in PAN+ Tre group, whereas it significantly increased in
Tre+CQ and Tre+WT groups. The immunoblot images were shown along with statistical data. *p,0.05, **p,0.01 versus Tre group, n = 7. (D) Necrosis
increased after the inhibition of trehalose-induced autophagy. The LDH in culture medium was measured. *p,0.05, **p,0.01 versus PAN+Tre group,
n = 6. (E) Podocyte apoptosis increased after the inhibition of trehalose-induced autophagy. The percentage of apoptotic podocytes was much
higher in PAN+Tre+CQ and PAN+Tre+WT groups than the PAN+ Tre group. *p,0.05, **p,0.01 versus PAN+ Tre group, n = 7. (F) The percentage of
active caspase-3 positive podocytes increased after inhibition of trehalose-induced autophagy. The changes in the percentage of active caspase-3
positive podocytes were similar to the data in (E). *p,0.05, **p,0.01 versus PAN+ Tre group, n = 8.
doi:10.1371/journal.pone.0113520.g005
Trehalose Alleviates Human Podocyte Injury
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e113520
been discovered. For instance, lithium, carbamazepine or valproic
acid induce autophagy by decreasing inositol via the inositol
signalling pathway [35]. L-type Ca2+ channel antagonists such as
verapamil, loperamide, amiodarone, nimodipine and nitrendipine
enhance autophagy by activating the Ca2+/Calpain pathway [36].
In addition, the cAMP/Epac/Ins (1, 4, 5) P3 pathway was also
reported [37]. However, it is still unknown which pathway is
involved in trehalose-induced autophagy. Thus, more studies are
needed to explore the underlying mechanisms.
ROS has been regarded as a common signalling molecular for
autophagy induction. For instance, starvation induces autophagy
via the production of ROS which specially regulates the activity of
Atg4 [27]. However, trehalose did not promote the generation of
ROS, suggesting no induction of cell stress in podocytes.
Consistently, it has been reported that ROS does not change
after trehalose treatment in HeLa cells [38]. In addition, our study
showed that the phosphorylation level of p-AMPK did not change
significantly, and no sign of the activation of AMPK was detected.
Therefore, our results suggested that trehalose induced autophagy
without changing the energy status and it may have fewer side
effects than other autophagy inducers.
In the present study, we used PAN-treated podocytes to test the
efficacy of trehalose, as this model is characterized by the
increased apoptosis and actin cytoskeleton rearrangement mim-
icking podocyte damage in glomerular diseases [9]. We found that
PAN slightly increased the expression of LC3-II at 48 h,
suggesting autophagy was also induced under cell stress, but it
was kept at a low level at this time point. Additionally, trehalose
can enhance autophagy in PAN-treated podocytes. As a result,
PAN-induced podocyte apoptosis was decreased by trehalose. This
finding was also confirmed by the percentage of active caspase-3
positive podocytes. Furthermore, two autophagy inhibitors (CQ
and WT) based on different principles were used for verifying the
role of trehalose-induced autophagy. The expression pattern of
LC3-II and p62 revealed that trehalose-induced autophagy was
blocked, but it may be puzzling that p62 was not elevated in PAN+
Tre+CQ and PAN+Tre+WT groups. The possible reason is that
p62 was partially degraded in advance by PAN which also induced
a low level of autophagy in podocytes at 48 h. Consequently,
necrosis increased and the decreased apoptosis by trehalose
rebounded after autophagy inhibition. Taken together, it suggest-
ed that trehalose decreased podocyte apoptosis via autophagy
induction. In future, more studies may be carried out to explore
how trehalose-induced autophagy decreases podocyte apoptosis.
As it has been reported that autophagy can decrease apoptosis by
inhibiting the production of active caspase 8 and tBid [39].
Moreover, autophagy eliminated dysfunctional mitochondria to
decrease the generation of cytochrome C which activates apoptosis
[40].
Actin cytoskeleton depolymerisation was another important
feature of glomerular diseases [41]. We showed that trehalose
partially reversed actin cytoskeleton reorganization and suppressed
the formation of lamellipodia which was associated with cell
motility. It is well known that podocytes are motile cells, but the
motility is kept at an optimal level. The enhanced motility is
detrimental to podocytes and is responsible for podocyte
Figure 6. Trehalose alleviated PAN-induced actin cytoskeleton injury in human podocytes. Podocyte were treated with PAN (30 mg/ml)
or/and Trehalose (50 mM) for 48 h. (A) F-actin was stained for evaluating the integrity of actin cytoskeleton. PAN induced actin cytoskeleton
depolymerisation which was characterized by irregular distribution of F-actin. Meanwhile, plenty of lamellipodias were formed (indicated by white
arrows). The actin cytoskeleton damages were partially reversed by trehalose. The representative F-actin staining images were shown. (B–C) PAN-
induced actin cytoskeleton damage in podocytes was alleviated by trehalose. The number of PAN-treated podocytes with disrupted actin
cytoskeleton was down-regulated by trehalose, accompanying with decreased lamellipodias. **p,0.01, ***p,0.001 versus CON, n= 6.
doi:10.1371/journal.pone.0113520.g006
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effacement in vivo [1]. The data of migration assay demonstrated
that PAN accelerated podocyte migration, whereas trehalose
decreased this enhanced motility to the normal level. Taken
together, it is suggested that trehalose also protected podocytes by
maintaining the stability and normal motility of actin cytoskeleton.
However, it is difficult to verify whether the cytoprotective effect in
podocyte actin cytoskeleton is attribute to trehalose-induced
autophagy, because autophagy inhibitors (CQ and WT) disrupted
actin cytoskeleton to similar extend as PAN alone at 48 h (data not
shown). Additionally, it has been reported that autophagy
inhibition (Atg7 knockout) lead to actin rearrangement in mouse
embryonic fibroblast cells [42]. Thus, our data showed that
trehalose can protect actin cytoskeleton in podocytes, but the
underlying mechanisms need to be investigated in the future.
In conclusion, trehalose induced autophagy and alleviated
podocyte injury including apoptosis and actin cytoskeleton
depolymerisation. Notably, trehalose may be safer than other
autophagy inducers, not only because it is a natural disaccharide
widespread throughout the biological world, but also it induced
autophagy independent of mTOR and ROS in human podocytes.
As mTOR is involved in diverse cell functions such as protein
synthesis, ribosome biogenesis and cell cycle, trehalose theoreti-
cally produces fewer side effects. On the contrary, rapamycin is a
strong autophagy inducer due to the inhibition of mTOR, and it
may partially explain why rapamycin achieves remission in
podocyte injury in vitro but it leads to proteinuria in patients
with renal transplantation [33]. Moreover, trehalose activated
autophagic flux without causing cell stress in human podocytes.
Therefore, we proposed that autophagy induction is a novel
strategy for the treatment of glomerular diseases and trehalose is a
good candidate for inducing autophagy in podocytes. In future
studies, the efficacy of trehalose could be tested in PAN nephrosis
rat and adriamycin nephropathy model. Hopefully, trehalose can
be applied to patients with MCNS and FSGS for alleviating
podocyte injury. However, autophagy is a double edged sword.
Over-activation of autophagy or prolonged autophagy induction
may lead to cell death. In future, the questions of how to minimise
this risk and how to precisely regulate autophagy induction need to
be addressed for autophagic therapy.
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